pharmaceuticals

health care

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary ...
Read Full Story »
Stock Split Image

What the Market is Telling MannKind (Updated)

MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week's news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has ...
Read Full Story »
76764023

MannKind Secures Future of Afrezza in Major Sanofi Deal

MannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin ...
Read Full Story »
research

Why the Exelixis Cancer Trial News Matters This Time

Cancer treatment developer Exelixis Inc. (NASDAQ: EXEL) is trading very heavy volume today and getting a sharp price boost following a positive result in a phase 3 pivotal trial of ...
Read Full Story »
cannabis

Washington State Issues First Retail Marijuana Licenses

Washington state issued its first retail marijuana licenses on Monday. The state's Liquor Control Board notified two dozen stores so they could prepare before they are allowed to open their ...
Read Full Story »
biotech

Vindication for MannKind on FDA Approval

After markets closed last Friday, MannKind Corp. (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control ...
Read Full Story »
biotech

MannKind’s Afrezza Inhaled Insulin Drug Gets FDA Approval

The U.S. Food and Drug Administration (FDA) late Friday afternoon announced that it has approved Afrezza, a rapid-acting, inhaled insulin power that improves glycemic control in adults with diabetes. The ...
Read Full Story »
biotech

The Real Attraction to Vertex After Cystic Fibrosis Success

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) reported Tuesday morning that two Phase 3 studies of the company's lumacaftor cystic fibrosis drug in combination with its Kalydeco ivacaftor drug showed statistically significant ...
Read Full Story »
145922793

The Affordable Care Act Is Working Big for These Six Companies

For all the shots the Affordable Care Act, or Obamacare, has taken, the inevitable march onward continues. Some data are starting to emerge since the implementation of parts of the ...
Read Full Story »
Pills

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

Binary events in the health care arena can be huge in determining just how well investors do and their stocks perform. Medical meetings, clinical data and of, course, decisions by ...
Read Full Story »
biotech

Top Biotech Stocks to Buy According to Portfolio Managers

After seeing three years of incredible outperformance, biotech investors had a pretty large comeuppance starting in late February that lasted almost two months. A new research report from Cowen suggests ...
Read Full Story »
pills

Valeant Offers Even More for Botox-Maker Allergan

Canada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this week. The latest offer, announced just minutes ago includes $72 ...
Read Full Story »
Pfizer logo

Pfizer’s Real Issue: Identity Crisis Against Peers

Pfizer Inc. (NYSE: PFE) looks like it is now out of the bid for AstraZeneca PLC (NYSE: AZN). Since this bid started coming out, Pfizer's stock has declined about 7%, ...
Read Full Story »
biotech

BioCryst Crushes It on Rare Immune Disorder Drug Trial

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema (HAE) met the primary efficacy endpoint, several secondary endpoints and ...
Read Full Story »
down market

Why You Buy Big Pharma If the Market Crashes

Defensive sectors have done well this year, with utilities leading the way. One of the reasons is that despite the market hitting new all-time highs, there remains a wall of ...
Read Full Story »